A second straight record close for the valve maker at $107.19, 1.3% above Thursday's peak. Medtronic rose 1.88% and Abbott 1.22% the same day, so the medtech bid was broad.
Moves: Nov 13, 2026 · Alpha Vantage daily close
Headquartered in Franklin Lakes, NJ Fiscal year ends September NYSE: BDX bd.com
Becton, Dickinson and Company (BD) is a pure-play medical technology company with more than 60,000 employees that delivers billions of products annually to healthcare providers worldwide. After the February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation, BD ('New BD') operates four segments:
- Medical Essentials: Medication Delivery Solutions and Specimen Management.
- Connected Care: Medication Management Solutions, including pharmacy automation such as the BD Vmax robot, and Advanced Patient Monitoring.
- BioPharma Systems: drug delivery systems for pharmaceutical companies.
- Interventional: Peripheral Intervention, Urology and Critical Care, and Surgery, including vascular stents and tissue regeneration products such as Phasix Mesh and GalaFLEX scaffolds.
About 60% of revenue comes from the United States. BD is executing its 'Excellence Unleashed' strategy and has committed to a multi-year U.S. manufacturing investment program in partnership with the U.S. Government. Updated
A second straight record close for the valve maker at $107.19, 1.3% above Thursday's peak. Medtronic rose 1.88% and Abbott 1.22% the same day, so the medtech bid was broad.
Moves: Nov 13, 2026 · Alpha Vantage daily close
The first full quarter of the slimmed down MedTech company beat on both lines, and management guided fiscal 2027 adjusted EPS to $13.10 to $13.30 against $12.70 last year. Free cash flow jumped 42.5%, the tell that the Life Sciences spin is paying off.
A 4.38% day adds roughly $2.4 billion to a $57 billion medtech name that rarely moves like this. Whether the $209.08 level holds into the next session is the thing to watch.
A 4.13% move to $208.57 adds roughly $2.3 billion to a $56.8 billion medtech name that rarely travels this far in a single session. Worth seeing whether it holds into the close.
Becton Dickinson closed at $193.76, a fresh 52-week high and 1.51% above the prior peak set on August 21. The $52.8 billion medtech name spent most of the spring in the $140s.
Hospitals reorder syringes, sensors, and implants whether the economy booms or stalls, and three device makers turn that habit into payouts that grow every year. Only one has a streak long enough…
Pre-Market Stock Futures: Futures are mixed this Friday morning, with the Dow Jones trading lower, but Nasdaq futures are higher as AI stocks catch a bid after the big post-election rally…
Most income investors chase flashy yields and overlook the quiet compounders that have raised their dividends through recessions, rate shocks, and global pandemics. Three healthcare stocks prove that the most reliable paycheck…
Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year. One…
Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made…
Jim Cramer just put a Brazilian mining giant in the same sentence as cryptocurrency, and his reasoning has everything to do with where he thinks inflation is headed next.
Four Dividend Aristocrats were flagged as stealth growth plays a year ago, and the results cut sharply in two directions. See which names delivered and which stumbled, plus three fresh picks where…
Wall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made…
Wall Street has gotten far more selective on AI stocks, but these AI stocks are still receiving the lion’s share of invested capital. Dividend Aristocrat stocks like PepsiCo (NASDAQ:PEP | PEP Price…
Dividend Kings are stocks that’ve had their dividend payouts raised for 50 consecutive years or more, such as Target (NYSE:TGT | TGT Price Prediction), Becton Dickinson (NYSE:BDX), and Hormel Foods (NYSE:HRL). That…
Dividend Aristocrats are some of the best stocks to buy when they go on sale, as they’re backed by companies on a solid footing. These companies have raised the dividends on their…
Wall Street feels these five Dividend Aristocrat stocks are the best values in the group and offer the best entry points for investors seeking dependable income with growth potential.
With all of the attention focused on the Magnificent 7 tech stocks, AI, and biotech stocks that are all high flying and turbo charging the S&P 500, it’s easy to overlook other…
As we enter the second half of 2025, now is the perfect time to invest in dividend stocks — especially those with quality underlying fundamentals that pay high dividend yields. Many such…
Certain stocks have declined significantly in the past few months as the economic cycle has been changing. The Federal Reserve seems well-positioned to do at least one rate cut this year. Inflation…
Becton, Dickinson and Company (BD) is a pure-play medical technology company with more than 60,000 employees that delivers billions of products annually to healthcare providers worldwide.
24/7 Wall St.'s 12-month price target for BDX is $264.50, rated Buy. The Wall Street consensus target is $226.14. BDX price prediction →